1152. Beraprost
Nomenclature
CAS number: 88430-50-6
2,3,3a,8b-Tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-cyclopenta(b)benzofuran-5-butanoic acid; dl-16-methyl-18,19-tetradehydro-5,6,7-trinor-4,8-inter-m-phenyleneprostaglandin I2; dl-4-[(1R,2R,3aS,8bS)-1,2,3a,8b-tetrahydro-2-hydroxy-[(3S,4RS)-3-hydroxy-4-methyl-oct-6-yne-(E)-1-enyl]-5-cyclopenta(b)benzofuranyl]butanoic acid; befaprost; ML-1229. C24H30O5; mol wt 398.49.
C 72.34%, H 7.59%, O 20.08%.
Description and references
Platelet aggregation inhibitor; stable analog of prostacyclin, q.v. Prepn: K. Ohno et al., EP 84856; eidem, US 4474802 (1983, 1984 both to Toray); eidem, Adv. Prostaglandin Thromboxane Leukotriene Res. 15, 279 (1985). PGI2 receptor binding: N. Kajikawa et al., Arzneim.-Forsch. 39, 495 (1989). Series of articles on pharmacology: ibid. 856-876. Clinical pharmacokinetics: J.-L. Demolis et al., J. Cardiovasc. Pharmacol. 22, 711 (1993). Clinical trial in intermittent claudication: M. Lievre et al., ibid. 27, 788 (1996); in diabetic angiopathy: Y. Okuda et al., Prostaglandins 52, 375 (1996).
Derivative
Sodium salt.Nomenclature
CAS number: 88475-69-8
ML-1129; TRK-100; Dorner (Toray); Procylin (Kaken). C24H29NaO5; mol wt 420.47.
C 68.56%, H 6.95%, Na 5.47%, O 19.03%.
Therapeutic Category
Antithrombotic; vasodilator (peripheral).
Keywords
Prostaglandin/Prostaglandin Analog; Vasodilator (Peripheral); Antithrombotic